Search PubMed⌕ Search

Biomedical subjects

J F Delaloye

Publications and source records attributed to J F Delaloye.

At least 37 records · Page 2Linked to original sources
PubMed1995

[Diagnosis and treatment of mastodynia].

Breast pain or mastalgia is a frequent complaint and it may represent various pathological conditions. After a thorough evaluation and reassurance of the patients, only those whose symptoms are severe enough to alter their life-style still require therapy. In some cases it will be indicated to modify or to stop an oral contraception or to adapt a hormone replacement therapy. Those women still resistant to treatment may experience relief from evening primrose oil supplements, bromocriptine, danazol, some progestins, tamoxifen or GnRH analogues. Therapy of non cyclic breast pain is made according to the underlying pathology. If no substrate is present, treatment is the same as for cyclical mastalgia but the response is diminished.

Adult↗
PubMed1994

[Autoimmune paraneoplastic cerebellar degeneration].

Paraneoplastic cerebellar degeneration is a well-defined clinical entity typically associated with ovarian or breast carcinoma. Serum or CSF of these patients has been shown to contain autoantibodies against the cytoplasm of Purkinje cells. These antibodies have been referred to as anti-Yo. We report the case of a 67-year old woman with ovarian adenocarcinoma presenting with subacute cerebellar dysfunction. Her serum was found to react with the cytoplasm of Purkinje cells and HeLa cells. On Western blot analysis a 60 to 70 kD reaction was obtained. This suggests the presence of a classical anti-Yo antibody.

Adenocarcinoma↗
PubMed1993

[Childbirth without fear in case of Von Willebrand's disease].

We report two cases of von Willebrand (type I) disease with vWF antigen levels of 21 and 25%, vWF ristocetin cofactor concentrations of 32 and 30%, and coagulation FVIII levels of 10 and 50% respectively. Template bleeding times were 20 and 11 minutes respectively. Both of these women exhibited a progressive and marked improvement of the vWF/FVIII complex during pregnancy. In the first, all parameters had completely normalized in the 37th week when a cesarean section was performed without hemorrhagic complications. The second case had borderline normal levels of the vWF/FVIII complex in the 37th week and underwent normal delivery in the 39th week. The improvement persisted for at least one week post-partum and in the first case values were still higher 10th weeks after delivery than they had been prior to the pregnancy. These observations and similar cases in the recent literature suggest that obstetrical operations and normal delivery are not associated with major blood losses in cases of moderately severe vWD of type I. These patients probably will not need vWF/FVIII concentrates for adequate hemostasis.

Adult↗
PubMed1993

Intraperitoneal carboplatin in advanced ovarian carcinoma.

24 patients with advanced epithelial ovarian cancer, who demonstrated a clinical complete or partial response to the induction of intravenous chemotherapy, underwent implantation of a subcutaneous semipermanent port-and-catheter system (Port-A-Cath) for intraperitoneal chemotherapy, which consisted of carboplatin 300 mg/m2 every 4 weeks. The median survival was 27.4 months for minimal residual disease versus 8 months for bulky disease (p = 0.0054). The median progression-free interval was 15.7 months for minimal residual disease versus 1.8 months for bulky disease (p = 0.008). There were 3 complications (12.5%) related to the catheter: 1 perforation of the large bowel and 2 catheter inflow obstructions. Myelosuppression, especially a grade 3 leucopenia in 5 patients (25%) and a grade 4 thrombopenia in 3 patients (15%), was the dose-limiting toxicity. Even with maximum cytoreductive surgery and second-line intraperitoneal carboplatin-based chemotherapy, the 5-year progression-free survival (4.1%) remains very small.

Aged↗
PubMed1993

An ovarian tumor of probable Wolffian origin.

The clinico-pathological features of one rare case of an ovarian tumor of probable Wolffian origin are reported. This tumor arises within the rete ovarii and is predominantly cystic on gross examination. Microscopically these cysts are lined by flattened epithelial cells and are separated by solid areas formed by large tubular glands. It is difficult to recognize this type of tumor on frozen section and to distinguish it from adenocarcinoma of the ovary. Surgery can be limited to total hysterectomy and bilateral salpingo-oophorectomy. No adjuvant therapy is necessary.

Adenocarcinoma↗
PubMed1991

Oral contraceptives and the risk of endometrial cancer.

The relationship between the use of combination oral contraceptives (OCs) and the risk of endometrial cancer was assessed in a case-control study conducted in the Swiss Canton of Vaud between 1 January 1988 and 31 July 1990. Subjects included 122 women aged 75 or less with histologically confirmed endometrial cancer, and 309 control women in hospital for acute conditions unrelated to OC use. Overall, 14 percent of cases and 27 percent of controls had ever used OCs, corresponding to a multivariate relative risk (RR) of 0.5 (95 percent confidence interval [CI]: 0.3, 0.8). The risk of endometrial cancer was found to be related inversely to duration of OC use: RR = 1.0 for less than two years of OC use; 0.5 for two to five years; and 0.3 (95 percent CI: 0.1, 0.7) for more than five years. The protection appeared greater within 20 years since last use, and the RR rose to 0.8 after 20 or more years since last use; numbers are too small, however, for reliable inference from these subanalyses. No significant interaction or modifying effect was observed with other major factors related to endometrial cancer, including parity, body mass index, estrogen replacement therapy, and cigarette smoking. While this study provides further evidence for the protective effect of OCs against risk of endometrial cancer, the relationship requires continued evaluation to assess the long-term implications and public health impact of OC use.

Age Factors↗